Pharmaceutical Technology

JUNE 19, 2023

UK-based pharmaceutical giant GSK has announced that the US Food and Drug Administration (FDA) has extended the review period of its new drug application (NDA) for the rare bone cancer drug momelotinib by three months. The drug is not currently approved in any markets globally.

Food and Drug Administration 98

Food and Drug Administration FDA Prescription Food 98

European Pharmaceutical Review

JANUARY 25, 2024

Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. This document is revised from a version published in October 2023.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Manufacturing 98

European Pharmaceutical Review

FEBRUARY 22, 2023

The hurdles encountered in development and approval of a new drug can be overwhelming. 1 Consequently, the US Food and Drug Administration (FDA) and other agencies are keen to see “accelerated development” programmes in areas where there is a significant unmet clinical need. billion, and rising. billion, and rising.

Food and Drug Administration 97

Food and Drug Administration FDA Safety Food 97

European Pharmaceutical Review

JUNE 26, 2023

US Food and Drug Administration (FDA) has published its first draft guidance presenting considerations to the pharmaceutical industry for designing clinical trials for psychedelic drugs. What recommendations are included in the draft guidance on psychedelic drugs? However, these are still investigational products.

Food and Drug Administration 98

Food and Drug Administration FDA Safety Food 98

European Pharmaceutical Review

JUNE 27, 2023

AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.

Food and Drug Administration 105

Food and Drug Administration Safety FDA Food 105

Pharmaceutical Technology

MAY 2, 2023

The US Food and Drug Administration (FDA) has accepted the supplemental biologics licence application submitted by Bristol Myers Squibb for Reblozyl (luspatercept-aamt) as a first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes (MDS).

Food and Drug Administration 98

Food and Drug Administration FDA Safety Prescription 98

Pharmaceutical Technology

APRIL 28, 2023

The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. The US agency previously granted the Orphan Drug Designation to EDIT-301 for its study in beta thalassemia, in May 2022.

Food and Drug Administration 105

Food and Drug Administration Engineering Patients Food 105

European Pharmaceutical Review

OCTOBER 18, 2023

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. XPHOZAH is expected to be available to eligible patients in the US in November 2023. It was investigated both as monotherapy and in combination with phosphate binder therapy.

Food and Drug Administration 119

Food and Drug Administration FDA Food Patients 119

Pharmaceutical Technology

MARCH 2, 2023

The US Food and Drug Administration (FDA) has approved Reata Pharmaceuticals ’ oral, once-daily medication SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia patients. SKYCLARYS is the first approved treatment in Friedrich’s Ataxia and marks a milestone for drug development in this complex disease.

Food and Drug Administration 105

Food and Drug Administration Pharmaceutical FDA Food 105

Pharmaceutical Technology

JUNE 9, 2023

Biopharmaceutical company Novaliq has received approval from the US Food and Drug Administration (FDA) for VEVYE (cyclosporine ophthalmic solution) 0.1% It has been designed to address the unmet needs of patients and to provide quick action and well-tolerated dry eye drug therapy.

Food and Drug Administration 98

Food and Drug Administration FDA Medical science Food 98

European Pharmaceutical Review

JANUARY 20, 2023

The US Food and Drug Administration (FDA) has issued a complete response letter for the accelerated approval submission of donanemab for early Alzheimer’s, Eli Lilly and Company revealed. In some cases, this occurred in less than 12 months, which is why fewer patients stayed on the drug for a full year.”

FDA 98

FDA Food and Drug Administration Safety Medicine 98

European Pharmaceutical Review

JULY 4, 2024

In the US, botanical dietary supplements can be sold without US Food and Drug Administration (FDA) approval, 1 prompting many vendors to promote the use of botanical products as dietary supplements , 2 rather than pursue a path of regulatory approval. 3 Is two too few?

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

European Pharmaceutical Review

OCTOBER 24, 2023

PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides the broadest serogroup coverage of any meningococcal vaccine available in the US for meningococcal disease in individuals aged 10 to 25 years old, has been approved by the US Food and Drug Administration (FDA).

Food and Drug Administration 105

Food and Drug Administration Safety Food FDA 105

European Pharmaceutical Review

OCTOBER 30, 2023

Moreover, no unexpected safety signal for the gene therapy was identified in the LGMD2I/R9 study. Additionally, these first results were also presented at the 2023 International Limb-Girdle Muscular Dystrophy Conference. ATA-100 has received an Investigational New Drug (IND) clearance by the US Food and Drug Administration (FDA).

Food and Drug Administration 98

Food and Drug Administration Safety Food FDA 98

European Pharmaceutical Review

DECEMBER 5, 2022

MOMENTUM was a randomised, double-blind Phase III clinical trial of momelotinib versus danazol in symptomatic and anaemic myelofibrosis patients treated with a US Food and Drug Administration (FDA)-approved JAK inhibitor. The post EMA accepts momelotinib marketing application appeared first on European Pharmaceutical Review.

Food and Drug Administration 97

Food and Drug Administration Marketing Food Medicine 97

European Pharmaceutical Review

JANUARY 23, 2025

billion, the agreement is the biggest biotech M&A transaction since 2023. For example, 2024 saw companies trying to tap innovation at an earlier point in the development cycle, and the industry turned away from the big deals for de-risked assets that characterised 2023. FDA Issues First Recommendations On AI For Drug Development.

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

Pharmaceutical Technology

APRIL 19, 2023

SAB Biotherapeutics has received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for SAB-176, an investigational immunotherapy to treat influenza. SAB-176 received fast-track designation from FDA in mid-April 2023.

Food and Drug Administration 105

Food and Drug Administration FDA Food Safety 105

European Pharmaceutical Review

DECEMBER 22, 2023

This represents a 53 percent premium on Karuna’s closing stock price on 21 December 2023. KarXT targets both the M1 and M4 muscarinic receptors, resulting in a differentiated safety and efficacy profile. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024.

Food and Drug Administration 98

Food and Drug Administration Side effects Safety Food 98

Pharmaceutical Technology

JULY 28, 2022

Many of the mainstay drugs for the treatment of moderate to severely active UC, such as anti-tumour necrosis factor (anti-TNF) agents like infliximab, target inflammatory mediators that are dysregulated in this condition. Data from the QUASAR induction study demonstrated positive efficacy and safety results.

Food and Drug Administration 98

Food and Drug Administration Safety Side effects Marketing 98

European Pharmaceutical Review

FEBRUARY 7, 2023

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-A501, an adeno-associated virus (AAV)-based gene therapy for Danon disease. “RP-A501 A Phase II trial is on track for the second quarter of 2023.

Food and Drug Administration 105

Food and Drug Administration FDA Medicine Food 105

Pharmaceutical Technology

NOVEMBER 7, 2022

“We are confident that they will be a great partner for us as we bring our treatment for Parkinson’s disease to the clinic in 2023.”. The open-label, dose-escalation trial will analyse the safety and tolerability of SNK02 in solid tumour patients who are refractory to standard-of-care treatment.

Food and Drug Administration 98

Food and Drug Administration Food Networking Safety 98

European Pharmaceutical Review

NOVEMBER 29, 2023

Following the US Food and Drug Administration (FDA)’s approval of Ferring Pharmaceuticals’ gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) in December 2022, new long-term follow up data has been revealed. These findings were presented at the 2023 Annual Meeting of the Society of Urologic Oncology (SUO).

Food and Drug Administration 114

Food and Drug Administration Pharmaceutical FDA Food 114

European Pharmaceutical Review

SEPTEMBER 18, 2023

The first and only treatment for anaemic patients with myelofibrosis has been approved by the US Food and Drug Administration (FDA). Phase III study SIMPLIFY-1 compared the safety and efficacy of momelotinib to ruxolitinib in patients with myelofibrosis who had not received prior treatment with a JAK inhibitor.

Food and Drug Administration 98

Food and Drug Administration Safety FDA Food 98

European Pharmaceutical Review

AUGUST 31, 2023

In addition, radionuclide therapy has the potential to achieve high efficacy rates since the administered drugs spare surrounding healthy tissue, thus, reducing the burden on the patient. 1-4 Besides these drug products, several companies worldwide are developing radiotheranostics in clinical trials built on various radionuclides.

Food and Drug Administration 97

Food and Drug Administration Manufacturing Safety Transportation 97

European Pharmaceutical Review

JANUARY 26, 2023

The ICH M10 guideline provides recommendations on the validation of bioanalytical assays for chemical and biological drugs and their metabolites in biological matrices. These concentration measurements are used as part of regulatory decisions regarding the safety and efficacy of medicinal products.

Food and Drug Administration 98

Food and Drug Administration Medicine Pharmaceutical products Pharmaceutical 98

Pharmaceutical Technology

JUNE 1, 2023

The US Food and Drug Administration (FDA) has granted a combination of AstraZeneca and MSD ’s Lynparza (olaparib), with standard therapies for treating BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). So far, 68 trials have been initiated in 2023.

Food and Drug Administration 97

Food and Drug Administration FDA Food Safety 97

European Pharmaceutical Review

FEBRUARY 2, 2024

ADUHELM was the “groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the [Alzheimer’s] field,” commented Christopher Viehbacher, President and Chief Executive Officer of Biogen. This follows granting of a marketing authorisation for the antibody therapy in Japan in September 2023.

Food and Drug Administration 97

Food and Drug Administration FDA Food Marketing 97

Pharmatutor

FEBRUARY 2, 2023

FDA Inspections - Overview admin Thu, 02/02/2023 - 13:52 FDA Inspection is a regulatory process conducted by the United States Food and Drug Administration (FDA) to evaluate the compliance of food and drug establishments with FDA regulations and standards.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

European Pharmaceutical Review

JUNE 29, 2023

Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. 1 Nitrosamines are not new or unknown impurities.

Food and Drug Administration 98

Food and Drug Administration Manufacturing Food Medicine 98

European Pharmaceutical Review

DECEMBER 6, 2022

If approved tofersen, an antisense medicine, could be the first drug to target the rare genetic cause of ALS, which affects less than 1,000 people in Europe and makes up around two percent of ALS cases. Biogen licensed tofersen from Ionis Pharmaceuticals, Inc. under a collaborative development and license agreement.

Marketing 98

Marketing Food and Drug Administration Medicine Prescription 98

European Pharmaceutical Review

JANUARY 29, 2024

In the published in 2023, the process and requirements for toxicological risk assessment of medical device constituents is outlined. Overall, the authors summarised that the enhanced sensitivity improves safety assessments for volatiles in medical devices.

Food and Drug Administration 98

Food and Drug Administration Medical Safety Food 98

European Pharmaceutical Review

JUNE 27, 2024

Looking back briefly to 2023, within the cell and gene therapy space, the US Food and Drug Administration (FDA) approved marketing authorisations for seven of these treatments. The number was 37, as of April this year. 1 One of these approvals was granted to Pfizer, Inc. The number was 37, as of April this year.

Food and Drug Administration 64

Food and Drug Administration Food Patients Marketing 64

European Pharmaceutical Review

AUGUST 22, 2023

The US Food and Drug Administration (FDA)-approved treatment, is the first RSV vaccine indicated for infants from birth to six months of age. In July 2023, the US government body approved the only monoclonal antibody for protection of infants in their first RSV season. US FDA granted approval of Abrysvo to Pfizer Inc.

Food and Drug Administration 98

Food and Drug Administration FDA Government Food 98

European Pharmaceutical Review

APRIL 16, 2024

In December 2023, the US Food and Drug Administration (FDA) approved the treatment for adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta was well tolerated with a favorable safety profile consistent with previously reported data, Novartis confirmed.

Food and Drug Administration 97

Food and Drug Administration Food Safety Medicine 97

European Pharmaceutical Review

DECEMBER 6, 2023

The US Food and Drug Administration (FDA) has approved the first oral monotherapy treatment for adults with paroxysmal nocturnal haemoglobinuria (PNH). Novartis’ Factor B inhibitor, Fabhalta ® (iptacopan) provides comprehensive control of red blood cell (RBC) destruction, according to the company. percent for anti-C5.

Food and Drug Administration 108

Food and Drug Administration Patients Physicians Food 108

European Pharmaceutical Review

JUNE 30, 2023

Roctavian, an adeno-associated virus (AAV) vector-based gene therapy is the first to be approved by the US Food and Drug Administration (FDA) for adults with severe haemophilia A. The gene therapy is authorised for individuals without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.

Food and Drug Administration 97

Food and Drug Administration FDA Food Safety 97

European Pharmaceutical Review

DECEMBER 14, 2023

This opinion was based on the results from the BRIGHT SKY programme, which included three Phase III clinical trials to monitor efficacy and safety in women with moderate to severe VMS. Fezolinetant, marketed as Veozah, received US Food and Drug Administration approval in May 2023. “We

Food and Drug Administration 96

Food and Drug Administration Biopharma Medicine Food 96